Platinum-Taxol non-cross resistance in epithelial ovarian cancer [PDF]
British Journal of Cancer, 1995 The aim of this study was to assess the clinical evidence for platinum-Taxol non-cross-resistance in patients with epithelial ovarian cancer. Unlike other studies, only patients who had demonstrably progressive disease on platinum therapy were analysed. Patients received 135-200 mg m-2 of Taxol over 3 or 24 h and all patients were assessed for response
Gore, M. E. +6 more
openaire +5 more sources
LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. [PDF]
Biosci Rep, 2018 Dysregulation of long non-coding RNAs (LncRNAs) participated into the initiation and progression of different diseases via direct regulation of proteins or indirect regulation of microRNA (miRNA)-target genes. LINC00473 is a novel carcinoma-related LncRNA and up-regulated in many cancers for tumor growth and metastasis, but its role in chemotherapy ...
Wang L, Zhang X, Sheng L, Qiu C, Luo R.
europepmc +4 more sources
Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells [PDF]
Drug Design, Development and Therapy, 2014 Yong-Wan Kim,1 Eun Young Kim,1 Doin Jeon,1 Juinn-Lin Liu,2 Helena Suhyun Kim,3 Jin Woo Choi,4 Woong Shick Ahn5 1Cancer Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea; 2Brain Tumor Center, Department of ...
Kim YW +6 more
doaj +5 more sources
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer [PDF]
Experimental and Molecular MedicineTriple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach.
Ozlem Yedier-Bayram +16 more
doaj +2 more sources
Down-regulated βIII-tubulin Expression Can Reverse Paclitaxel Resistance in A549/Taxol Cells Lines [PDF]
Chinese Journal of Lung Cancer, 2014 Background and objective Chemotherapy drug resistance is the primary causes of death in patients with pulmonary carcinoma which make tumor recurrence or metastasis. β-tubulin is the main cell targets of anti-microtubule drug. Increased expression of βIII-
Yinling ZHUO, Qisen GUO
doaj +2 more sources
Structure-Based Drug Design and Synthesis of Novel N‑Aryl-2,4-bithiazole-2-amine CYP1B1-Selective Inhibitors in Overcoming Taxol Resistance in A549 Cells [PDF]
As a promising therapeutic target for cancer, CYP1B1 is overexpressed in Taxol-resistant A549 cells; however, its role in drug resistance still remains unclear.
Fengjiao Zhang (1605394) +8 more
core +25 more sources
Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma. [PDF]
Oncol Lett, 2015 The development of chemoresistance in patients represents a major challenge in cancer treatment. Lactate dehydrogenase-A (LDHA) is one of the principle isoforms of LDH that is expressed in breast tissue, controlling the conversion of pyruvate to lactate and also playing a significant role in the metabolism of glucose.
Feng L +6 more
europepmc +4 more sources
Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway [PDF]
Cellular Oncology (Dordrecht)Yang Yuxi, Chu Maoquan
exaly +2 more sources
Mdivi-1 induces spindle abnormalities and augments taxol cytotoxicity in MDA-MB-231 cells
Cell Death Discovery, 2021 Taxol is a first-line chemotherapeutic for numerous cancers, including the highly refractory triple-negative breast cancer (TNBC). However, it is often associated with toxic side effects and chemoresistance in breast cancer patients, which greatly limits
Chieh-Ting Fang +4 more
doaj +1 more source
Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. [PDF]
PLoS ONE, 2014 Drug resistance is an obstacle to the effective treatment of ovarian cancer. We and others have shown that the insulin-like growth factor (IGF) signaling pathway is a novel potential target to overcome drug resistance.
Jurriaan Brouwer-Visser +5 more
doaj +1 more source